C4 Therapeutics Inc Ordinary Shares CCCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CCCC is a good fit for your portfolio.
News
-
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
-
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
-
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
-
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
-
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
Thinking about buying stock in C4 Therapeutics, Safety Shot, Intuitive Machines, Cardiol Therapeutics, or Iovance Biotherapeutics?
-
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance
Trading Information
- Previous Close Price
- $6.42
- Day Range
- $6.57–6.93
- 52-Week Range
- $1.06–11.85
- Bid/Ask
- $6.70 / $6.71
- Market Cap
- $461.00 Mil
- Volume/Avg
- 574,428 / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.38
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 145
- Website
- https://www.c4therapeutics.com
Comparables
Valuation
|
Metric
|
CCCC
|
ARVN
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.58 | 3.34 | 0.79 |
Price/Sales | 15.38 | 22.93 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CCCC
ARVN
VOR
Financial Strength
|
Metric
|
CCCC
|
ARVN
|
VOR
|
|---|---|---|---|
Quick Ratio | 6.21 | 4.93 | 8.81 |
Current Ratio | 6.34 | 4.98 | 9.04 |
Interest Coverage | −101.71 | — | — |
Quick Ratio
CCCC
ARVN
VOR
Profitability
|
Metric
|
CCCC
|
ARVN
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −28.90% | −26.31% | −41.83% |
Return on Equity (Normalized) | −44.28% | −58.35% | −51.69% |
Return on Invested Capital (Normalized) | −35.57% | −63.59% | −47.03% |
Return on Assets
CCCC
ARVN
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfmfhckq | Ljw | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pmyrgll | Hgxfwmj | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Trdxgmxzn | Wwkyww | $103.3 Bil | |
MRNA
| Moderna Inc | Hnmvxzxpl | Xrxx | $48.1 Bil | |
ARGX
| argenx SE ADR | Kcgtzyvr | Rtsbb | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Rcpnkkz | Bhdl | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Llcnrhgh | Tlrwn | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fvlbmltp | Zvmxjw | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mgljttvh | Qvlxpr | $12.7 Bil | |
INCY
| Incyte Corp | Gsgwjnhqv | Jcfjwm | $11.9 Bil |